4.4 Review

Use of hepadnavirus core proteins as vaccine platforms

Journal

EXPERT REVIEW OF VACCINES
Volume 8, Issue 11, Pages 1565-1573

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1586/ERV.09.121

Keywords

HBcAg; HBV subunit vaccine platform; virus-like particle; WHcAg

Categories

Funding

  1. NIAID NIH HHS [R43 AI072785, R01 AI049730-08, R43 AI072785-02, R01 AI049730, R01 AI020720, R01 AI020720-27] Funding Source: Medline

Ask authors/readers for more resources

The first virus-like particle to be tested for use as a vaccine carrier was based on the hepatitis B virus nucleocapsid protein. This viral subunit, while not infectious on its own, is a 36-nm particle that is highly immunogenic during a natural infection. The self-assembly and high degree of immunogenicity is maintained when expressed as a recombinant protein and, moreover, can confer a high degree of immunogenicity on foreign antigens linked to the particle, either chemically or genetically. This review describes the current state of the hepadnaviral core protein as a vaccine carrier.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available